Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

NCT00660920 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia
Hematologic Malignancies

Interventions

DRUG: Ponatinib

Sponsor

Ariad Pharmaceuticals